Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | BLK | P51451 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TEC | P42680 | 1/20 | 0.43 |
| ▸ | TXK | P42681 | 1/20 | 0.43 |
| ▸ | BMX | P51813 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22676631 | 0.88 | BTK (0.53) | BTKKCNH2EGFRBLKERBB2 | |
| SCHEMBL30582627 | 0.87 | BTK (0.49) | BTKKCNH2EGFRBLKERBB2 | |
| SCHEMBL30582582 | 0.87 | SRC (0.43) | BTKKCNH2EGFRRET | |
| SCHEMBL26105238 | 0.87 | SRC (0.43) | BTKKCNH2EGFRRET | |
| SCHEMBL22676199 | 0.87 | BTK (0.53) | BTKKCNH2EGFRBLKERBB2 | |
| SCHEMBL22673416 | 0.87 | BTK (0.53) | BTKKCNH2EGFRBLKERBB2 | |
| SCHEMBL22659060 | 0.87 | BTK (0.53) | BTKKCNH2EGFRBLKERBB2 | |
| SCHEMBL26113306 | 0.83 | BTK (0.40) | BTKKCNH2EGFRBLKERBB2 | |
| SCHEMBL30582591 | 0.83 | LCK (0.42) | BTKEGFRBLKERBB2RET | |
| SCHEMBL26108281 | 0.83 | LCK (0.42) | BTKEGFRBLKERBB2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | claimed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |